Breast Implant-associated Anaplastic Large Cell Lymphoma (BIA-ALCL) Registry
1 other identifier
observational
150
2 countries
31
Brief Summary
Anaplastic large cell lymphoma associated with breast implants (BIA-ALCL) is a rare disease seen only in women with a breast implant. Because of the low incidence of this disease and the peculiar histological subtype, French authorities, in accordance with the recommendations of an expert group, recommended the implementation of a BIA-ALCL case registry, in connection with a national Multidisciplinary meeting (Réunion de Concertation Pluridisciplinaire nationale de recours- RCP). This registry is opened in France and in Belgium
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Jun 2017
Longer than P75 for all trials
31 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 7, 2017
CompletedFirst Submitted
Initial submission to the registry
January 6, 2020
CompletedFirst Posted
Study publicly available on registry
January 7, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 7, 2032
ExpectedStudy Completion
Last participant's last visit for all outcomes
June 7, 2032
January 14, 2026
January 1, 2026
15 years
January 6, 2020
January 12, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Overall response
13 years
Study Arms (1)
BIA-ALCL
Interventions
Eligibility Criteria
Adult patients with an anaplastic large cell lymphoma associated with breast implants
You may qualify if:
- Adult patients with an anaplastic large cell lymphoma associated with breast implants
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (31)
A. Z. Sint-Jan Brugge-Oostende AV
Bruges, Belgium
Clinique Universitaire Saint LUC
Brussels, Belgium
Cliniques Universitaires de Bruxelles - Hôpital Erasme
Brussels, Belgium
Institut Jules Bordet
Brussels, Belgium
Universitair Ziekenhuis Brussel
Brussels, Belgium
Universitair Ziekenhuis Antwerpen
Edegem, Belgium
Universitair Ziekenhuis Gent
Ghent, Belgium
U.Z. Leuven - Campus Gasthuisberg
Leuven, Belgium
CHU de Liège -Domaine Sart Tilman
Liège, Belgium
CHU UCL Namur - Site Godinne
Yvoir, Belgium
CH d Avignon - Hopital Henri Duffaut
Avignon, France
Institut Bergonié
Bordeaux, France
CHRU de Brest - Hôpital Morvan
Brest, France
Hopital Louis Pasteur
Colmar, France
APHP - Hopital Henri Mondor
Créteil, France
CHU de Dijon - Hôpital le Bocage
Dijon, 21034, France
Centre Médical la Roseraie
Lille, France
Centre Léon Bérard
Lyon, France
Institut Paoli Calmettes
Marseille, France
CH Saint-Eloi
Montpellier, France
CHU de Nantes - Hôtel Dieu
Nantes, France
Hôpital Cochin
Paris, France
CH de Pau
Pau, France
CH de Perpigan
Perpignan, France
Centre Hospitalier Lyon Sud
Pierre-Bénite, France
Chu de Reims - Hopital Robert Debre
Reims, France
Centre Henri Becquerel
Rouen, France
Centre Rene Hugenin
Saint-Cloud, 92210, France
CH de Saint Malo
St-Malo, France
CHRU de Strasbourg
Strasbourg, 67100, France
Institut Universitaire du Cancer - Oncopole Toulouse (IUCT-O)
Toulouse, France
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- OTHER
- Target Duration
- 13 Years
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 6, 2020
First Posted
January 7, 2020
Study Start
June 7, 2017
Primary Completion (Estimated)
June 7, 2032
Study Completion (Estimated)
June 7, 2032
Last Updated
January 14, 2026
Record last verified: 2026-01
Data Sharing
- IPD Sharing
- Will not share